Furthermore, the treatment group of the FFPE-RNA application cohort was relatively small, which precluded demonstration of known predictive associations for anti-EGFR therapy per CMS and led to grouping of CMS2 and CMS3 samples (epithelial tumors) versus CMS1 and CMS4 samples (immune and mesenchymal tumors). Here, EGFR is linked to mesenchymal cell neoplasm.